Detecting radiation esophagitis using 18F-FAPI-04 PET/CT in patients with LA-ESCC treated with concurrent chemoradiotherapy

Abstract Purpose This prospective study examined whether 18F-AlF-NOTA-fibroblast activation protein inhibitor (FAPI)-04 (denoted as 18F-FAPI-04) positron emission tomography/computed tomography (PET/CT) can detect the development and severity of radiation esophagitis (RE) in patients with locally ad...

Full description

Saved in:
Bibliographic Details
Main Authors: Xinying Hu, Chao Han, Mingquan Zhang, Jing Jia, Zhengshuai Mu, Zheng Fu, Kailin Qiao, Jinming Yu, Yuchun Wei
Format: Article
Language:English
Published: BMC 2025-05-01
Series:BMC Cancer
Subjects:
Online Access:https://doi.org/10.1186/s12885-025-14236-3
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849335670195093504
author Xinying Hu
Chao Han
Mingquan Zhang
Jing Jia
Zhengshuai Mu
Zheng Fu
Kailin Qiao
Jinming Yu
Yuchun Wei
author_facet Xinying Hu
Chao Han
Mingquan Zhang
Jing Jia
Zhengshuai Mu
Zheng Fu
Kailin Qiao
Jinming Yu
Yuchun Wei
author_sort Xinying Hu
collection DOAJ
description Abstract Purpose This prospective study examined whether 18F-AlF-NOTA-fibroblast activation protein inhibitor (FAPI)-04 (denoted as 18F-FAPI-04) positron emission tomography/computed tomography (PET/CT) can detect the development and severity of radiation esophagitis (RE) in patients with locally advanced esophageal squamous cell carcinoma (LA-ESCC) treated with concurrent chemoradiotherapy. Materials and methods From June 2021 to March 2022, images were collected from LA-ESCC patients who underwent 18F-FAPI-04 PET/CT examinations before and during radiotherapy. The development of RE was evaluated weekly according to Radiation Therapy Oncology Group criterion. The target-to-background ratio in blood (TBRblood) was analyzed at each time point and correlated with the onset and severity of RE. Factors that predicted RE were identified by multivariate logistic analyses. Results Thirty patients were evaluated. Significantly higher TBRblood (during radiotherapy, P = 0.003) and change in TBRblood compared with pre-RT (ΔTBRblood, P = 0.002) were observed in patients with RE than patients without RE. Those with grade 3 RE had a significantly higher TBRblood (during radiotherapy, P = 0.003) and ΔTBRblood (P = 0.003) compared with those with RE < grade 3. On multivariate analysis, ΔTBRblood was identified as a significant detection of any grade RE (P = 0.021) and grade 3 RE (P = 0.038). Conclusion The ΔTBRblood on 18F-FAPI-04 PET/CT may be effective at identifying patients with RE, especially grade 3 RE.
format Article
id doaj-art-526fa735d7e946f8a222bca6732de1a1
institution Kabale University
issn 1471-2407
language English
publishDate 2025-05-01
publisher BMC
record_format Article
series BMC Cancer
spelling doaj-art-526fa735d7e946f8a222bca6732de1a12025-08-20T03:45:11ZengBMCBMC Cancer1471-24072025-05-0125111010.1186/s12885-025-14236-3Detecting radiation esophagitis using 18F-FAPI-04 PET/CT in patients with LA-ESCC treated with concurrent chemoradiotherapyXinying Hu0Chao Han1Mingquan Zhang2Jing Jia3Zhengshuai Mu4Zheng Fu5Kailin Qiao6Jinming Yu7Yuchun Wei8Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong Provincial Key Laboratory of Precision Oncology, Shandong First Medical University, Shandong Academy of Medical SciencesBreast Cancer Center, Shandong Cancer Hospital and Institute, Shandong First Medical University, Shandong Academy of Medical SciencesDepartment of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong Provincial Key Laboratory of Precision Oncology, Shandong First Medical University, Shandong Academy of Medical SciencesDepartment of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong Provincial Key Laboratory of Precision Oncology, Shandong First Medical University, Shandong Academy of Medical SciencesDepartment of Pathology, Shandong Cancer Hospital and Institute, Shandong First Medical University, Shandong Academy of Medical SciencesDepartment of PET/CT Center, Shandong Cancer Hospital and Institute, Shandong First Medical University, Shandong Academy of Medical SciencesDepartment of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong Provincial Key Laboratory of Precision Oncology, Shandong First Medical University, Shandong Academy of Medical SciencesDepartment of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong Provincial Key Laboratory of Precision Oncology, Shandong First Medical University, Shandong Academy of Medical SciencesDepartment of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong Provincial Key Laboratory of Precision Oncology, Shandong First Medical University, Shandong Academy of Medical SciencesAbstract Purpose This prospective study examined whether 18F-AlF-NOTA-fibroblast activation protein inhibitor (FAPI)-04 (denoted as 18F-FAPI-04) positron emission tomography/computed tomography (PET/CT) can detect the development and severity of radiation esophagitis (RE) in patients with locally advanced esophageal squamous cell carcinoma (LA-ESCC) treated with concurrent chemoradiotherapy. Materials and methods From June 2021 to March 2022, images were collected from LA-ESCC patients who underwent 18F-FAPI-04 PET/CT examinations before and during radiotherapy. The development of RE was evaluated weekly according to Radiation Therapy Oncology Group criterion. The target-to-background ratio in blood (TBRblood) was analyzed at each time point and correlated with the onset and severity of RE. Factors that predicted RE were identified by multivariate logistic analyses. Results Thirty patients were evaluated. Significantly higher TBRblood (during radiotherapy, P = 0.003) and change in TBRblood compared with pre-RT (ΔTBRblood, P = 0.002) were observed in patients with RE than patients without RE. Those with grade 3 RE had a significantly higher TBRblood (during radiotherapy, P = 0.003) and ΔTBRblood (P = 0.003) compared with those with RE < grade 3. On multivariate analysis, ΔTBRblood was identified as a significant detection of any grade RE (P = 0.021) and grade 3 RE (P = 0.038). Conclusion The ΔTBRblood on 18F-FAPI-04 PET/CT may be effective at identifying patients with RE, especially grade 3 RE.https://doi.org/10.1186/s12885-025-14236-3Fibroblast activation proteinPositron emission tomographyChemoradiotherapyEsophageal squamous cell carcinomaRadiation esophagitis
spellingShingle Xinying Hu
Chao Han
Mingquan Zhang
Jing Jia
Zhengshuai Mu
Zheng Fu
Kailin Qiao
Jinming Yu
Yuchun Wei
Detecting radiation esophagitis using 18F-FAPI-04 PET/CT in patients with LA-ESCC treated with concurrent chemoradiotherapy
BMC Cancer
Fibroblast activation protein
Positron emission tomography
Chemoradiotherapy
Esophageal squamous cell carcinoma
Radiation esophagitis
title Detecting radiation esophagitis using 18F-FAPI-04 PET/CT in patients with LA-ESCC treated with concurrent chemoradiotherapy
title_full Detecting radiation esophagitis using 18F-FAPI-04 PET/CT in patients with LA-ESCC treated with concurrent chemoradiotherapy
title_fullStr Detecting radiation esophagitis using 18F-FAPI-04 PET/CT in patients with LA-ESCC treated with concurrent chemoradiotherapy
title_full_unstemmed Detecting radiation esophagitis using 18F-FAPI-04 PET/CT in patients with LA-ESCC treated with concurrent chemoradiotherapy
title_short Detecting radiation esophagitis using 18F-FAPI-04 PET/CT in patients with LA-ESCC treated with concurrent chemoradiotherapy
title_sort detecting radiation esophagitis using 18f fapi 04 pet ct in patients with la escc treated with concurrent chemoradiotherapy
topic Fibroblast activation protein
Positron emission tomography
Chemoradiotherapy
Esophageal squamous cell carcinoma
Radiation esophagitis
url https://doi.org/10.1186/s12885-025-14236-3
work_keys_str_mv AT xinyinghu detectingradiationesophagitisusing18ffapi04petctinpatientswithlaescctreatedwithconcurrentchemoradiotherapy
AT chaohan detectingradiationesophagitisusing18ffapi04petctinpatientswithlaescctreatedwithconcurrentchemoradiotherapy
AT mingquanzhang detectingradiationesophagitisusing18ffapi04petctinpatientswithlaescctreatedwithconcurrentchemoradiotherapy
AT jingjia detectingradiationesophagitisusing18ffapi04petctinpatientswithlaescctreatedwithconcurrentchemoradiotherapy
AT zhengshuaimu detectingradiationesophagitisusing18ffapi04petctinpatientswithlaescctreatedwithconcurrentchemoradiotherapy
AT zhengfu detectingradiationesophagitisusing18ffapi04petctinpatientswithlaescctreatedwithconcurrentchemoradiotherapy
AT kailinqiao detectingradiationesophagitisusing18ffapi04petctinpatientswithlaescctreatedwithconcurrentchemoradiotherapy
AT jinmingyu detectingradiationesophagitisusing18ffapi04petctinpatientswithlaescctreatedwithconcurrentchemoradiotherapy
AT yuchunwei detectingradiationesophagitisusing18ffapi04petctinpatientswithlaescctreatedwithconcurrentchemoradiotherapy